EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Mycophenolic acid treatment drives the emergence of novel SARS-CoV-2 variants

Toni Luise Meister iD, Maximilian K Nocke iD, Natalie Heinen, Thomas L Burkard, Yannick Brüggemann, Saskia Westhoven, Bettina Trüeb iD, Nadine Ebert iD, Lisa Thomann iD, Krzysztof P Lubieniecki, Joanna M Lubieniecka, Kristina Döring und 15 weitere

Proceedings of the National Academy of Sciences · 15.07.2025 · 122 (28)

DOI: 10.1073/pnas.2500276122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 09.07.2025. Verfasst von Toni Luise Meister und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department for Molecular and Medical Virology, Ruhr University Bochum, Bochum 44801, Germany. Hauptthemen laut MEDLINE: Mycophenolic Acid, SARS-CoV-2, Immunosuppressive Agents, COVID-19 Drug Treatment. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Deutsche Forschungsgemeinschaft (DFG), Bundesministerium für Bildung und Forschung (BMBF), Ministerium für Kultur und Wissenschaft des Landes Nordrhein-Westfalen (MKW).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mycophenolic acid (MPA) is commonly used in immunosuppressive regimens following solid organ transplantation. We demonstrate that MPA treatment reproducibly inhibits the replication of a range of viruses, including severe respiratory syndrome coronavirus 2 (SARS-CoV-2). Mechanistically, we identified cellular guanosine triphosphate pool depletion as a key mediator of this antiviral effect. Strikingly, this inhibition can be overcome which was correlated with the emergence of three breakthrough mutations in the SARS-CoV-2 genome (S P812R, ORF3 Q185H, and E S6L). Subsequent analyses confirmed that the combination of these mutations conferred accelerated replication kinetics, higher viral titers, and more rapid onset of cytopathic effects, but not MPA resistance. Comparison of global transcriptional responses to infection highlighted dysregulation of specific cellular gene programs under MPA treatment prior to breakthrough mutation emergence. Together, these findings identify viral and host drivers of variant emergence under immunosuppression. They also advocate for close monitoring of immunosuppressed patients, where emergence of novel viral variants with a fitness advantage may arise.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycophenolic AcidSARS-CoV-2Immunosuppressive AgentsCOVID-19 Drug TreatmentAntiviral AgentsHumansCOVID-19Virus ReplicationMutationAnimalsGenome, ViralVero CellsChlorocebus aethiops

Stichwörter der Autor:innen

SARS-CoV-2guanosine triphosphate (GTP) depletionimmunosuppressionmycophenolic acidnovel variants

Substanzen

Mycophenolic AcidImmunosuppressive AgentsAntiviral Agents

Autor:innen und Institutionen

  • Department for Molecular and Medical Virology, Ruhr University Bochum, Bochum 44801, Germany.
  • Institute for Infection Research and Vaccine Development, Centre for Internal Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg 20251, Germany.
  • Department for Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine, Hamburg 20359, Germany.
  • German Centre for Infection Research (Deutsches Zentrum für Infektionsforschung), Partner Site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany.
  • Department of Translational and Computational Infection Research, Ruhr University Bochum, Bochum 44801, Germany.
  • European Virus Bioinformatics Centre, Jena 07743, Germany.

ORCID-Profile: Toni Luise Meister, Maximilian K Nocke, Bettina Trüeb, Nadine Ebert, Lisa Thomann, Maike Herrmann, Sibylle Haid, Thomas Pietschmann, Ingo Drexler, Huu Phuc Nguyen, Richard J P Brown, Daniel Todt

Förderung

  • Deutsche Forschungsgemeinschaft (DFG)
  • Bundesministerium für Bildung und Forschung (BMBF)
  • Ministerium für Kultur und Wissenschaft des Landes Nordrhein-Westfalen (MKW)
  • Ministerium für Arbeit, Gesundheit und Soziales des Landes Nordrhein-Westfalen

Zitieren

APA

Meister, T. L., Nocke, M. K., Heinen, N., Burkard, T. L., Brüggemann, Y., Westhoven, S., Trüeb, B., Ebert, N., Thomann, L., Lubieniecki, K. P., Lubieniecka, J. M., Döring, K., Herrmann, M., Haid, S., Pietschmann, T., Wiegmann, B., Tao, R., Pfefferle, S., Addo, M. M., …, & Pfaender, S. (2025). Mycophenolic acid treatment drives the emergence of novel SARS-CoV-2 variants. Proceedings of the National Academy of Sciences, 122(28). https://doi.org/10.1073/pnas.2500276122

Vancouver

Meister TL, Nocke MK, Heinen N, Burkard TL, Brüggemann Y, Westhoven S, et al. Mycophenolic acid treatment drives the emergence of novel SARS-CoV-2 variants. Proceedings of the National Academy of Sciences. 2025;122(28). doi:10.1073/pnas.2500276122

BibTeX
@article{Meister2025,
  author = {Meister, Toni Luise and Nocke, Maximilian K and Heinen, Natalie and Burkard, Thomas L and Brüggemann, Yannick and Westhoven, Saskia and Trüeb, Bettina and Ebert, Nadine and Thomann, Lisa and Lubieniecki, Krzysztof P and Lubieniecka, Joanna M and Döring, Kristina and Herrmann, Maike and Haid, Sibylle and Pietschmann, Thomas and Wiegmann, Bettina and Tao, Ronny and Pfefferle, Susanne and Addo, Marylyn M and Thiel, Volker and Drexler, Ingo and Babel, Nina and Phuc Nguyen, Huu and Brown, Richard J P and Todt, Daniel and Steinmann, Eike and Pfaender, Stephanie},
  title = {Mycophenolic acid treatment drives the emergence of novel SARS-CoV-2 variants},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2025},
  volume = {122},
  number = {28},
  doi = {10.1073/pnas.2500276122}
}
Kostenlos starten →